New treatment for antibody-mediated rejection: interleukin-6 inhibitors
Author:
Affiliation:
1. Division of Nephrology, Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea
2. Transplantation Research Institute, Kosin University College of Medicine, Busan, Korea
Funder
Korean Society for Transplantation
Publisher
The Korean Society for Transplantation
Link
https://pdf.medrang.co.kr/JKST/2024/038/ctr-38-1-1.pdf
Reference22 articles.
1. Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Renal Allograft Rejection: Accumulation of Antibody-neutralized Interleukin-6 Without Signs of Proinflammatory Rebound Phenomena
2. Mechanism and treatment for chronic antibody‐mediated rejection in kidney transplant recipients
3. Current Therapies in Kidney Transplant Rejection
4. The Korean Society of Nephrology. Clinical nephrology. 3rd ed. The Korean Society of Nephrology; 2022.
5. A Randomized Clinical Trial of Anti–IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3